Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.655 -0.155 (-4.07%) Market Cap: 47.36 Mil Enterprise Value: 104.79 Mil PE Ratio: 4.02 PB Ratio: 0.19 GF Score: 62/100

Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 12:00AM GMT
Release Date Price: $59.55 (+2.21%)
Ekaterina V. Knyazkova
JP Morgan Chase & Co, Research Division - Analyst

Hi, everyone. Good afternoon. I'm Ekaterina Knyazkova from the pharma team here at JPMorgan. Pleased to be introducing Eagle. And from Eagle, we have the company's CEO, Scott Tarriff.

A reminder that after the presentation, we're going to have a breakout session in the Olympic Room. And with that, I will turn it over to Scott.

Scott L. Tarriff
Eagle Pharmaceuticals, Inc. - Founder, CEO & Director

Well, thank you. Thank you very much, and everyone at JPMorgan for inviting us again today. So I see we have about 24 minutes. I don't know how we're going to get through everything that's been going on at the company in the next 24 minutes. But welcome, and thank you for joining us. So good afternoon.

And what you're going to see today, maybe I'll just set it up this way, that it's a very exciting time for the company. I hope you agree by the time we get done with this session. But so Eagle has been around for 14 years now. We've been public for about the last 5. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot